Nutritional Supplement

Chondroitin Sulfate for Sports & Fitness

Chondroitin Sulfate
  • Joint Health

    Osteoarthritis

    Many trials have shown that supplementing with chondroitin sulfate reduces pain, increases joint mobility, and promotes healing within the joints.
    Osteoarthritis
    ×

    Chondroitin sulfate (CS) is a major component of the lining of joints. The structure of CS includes molecules related to glucosamine sulfate. CS levels have been reported to be reduced in joint cartilage affected by osteoarthritis. Possibly as a result, CS supplementation may help restore joint function in people with osteoarthritis.3 On the basis of preliminary evidence, researchers had believed that oral CS was not absorbed in humans;4 as a result, early double-blind CS research was done mostly by giving injections.3,6 This research documented clinical benefits from CS injections. It now appears, however, that a significant amount of CS is absorbable in humans,7 though dissolving CS in water leads to better absorption than swallowing whole pills.8

    Strong clinical evidence now supports the use of oral CS supplements for osteoarthritis. Many double-blind trials have shown that CS supplementation consistently reduces pain, increases joint mobility, and/or shows evidence (including X-ray changes) of healing within joints of people with osteoarthritis.9,10,11,12,13,14,15,16,17,18,19 Most trials have used 400 mg of CS taken two to three times per day. One trial found that taking the full daily amount (1,200 mg) at one time was as effective as taking 400 mg three times per day.12 Reduction in symptoms typically occurs within several months.

  • Heart and Circulatory Health

    High Cholesterol

    Chondroitin sulfate appears to sequester cholesterol, lowering circulating cholesterol levels and reducing atherosclerosis.
    High Cholesterol
    ×
    Chondroitin sulfate is a large structural polysaccharide found in connective tissues including in blood vessel walls, where it appears to form complexes with cholesterol that contribute to atherosclerosis.19 Clinical trials performed in the 1960s and 1970s reported supplemental chondroitin sulfate had cholesterol-lowering effects and could slow atherosclerosis progression.20 For example, in one controlled trial that included 48 elderly participants with atherosclerosis, those given 4.5 grams of chondroitin sulfate daily had lower cholesterol levels, slower clotting times, and a lower mortality rate after 64 months.21 Another trial found chondroitin sulfate reduced the risk of coronary events (heart attack or serious episode of low blood flow to the heart) seven-fold during six years of monitoring.22 More recently, a trial in 48 subjects with obesity and knee osteoarthritis found eight weeks of supplementation with 600 mg of chondroitin sulfate daily not only reduced knee pain and dysfunction but also lowered total cholesterol levels and improved markers of inflammation and glucose metabolism relative to placebo.23 Some evidence suggests chondroitin sulfate interacts with LDL-cholesterol, reduces cholesterol accumulation in vessel walls, and decreases lipoprotein oxidation.24,25,26

    Atherosclerosis

    Preliminary research shows that chondroitin sulfate may prevent atherosclerosis and may also prevent heart attacks in people who already have atherosclerosis.
    Atherosclerosis
    ×
     

    Preliminary research shows that chondroitin sulfate may prevent atherosclerosis in animals and humans and may also prevent heart attacks in people who already have atherosclerosis.27,28 However, further research is needed to determine the value of chondroitin sulfate supplements for preventing or treating atherosclerosis.

    Heart Attack

    Taking chondroitin sulfate may reduce the risk of heart attack in people with a history of heart disease or who are at risk for heart attack.
    Heart Attack
    ×
    Years ago, researchers reported that taking for six years substantially reduced the risk of fatal and nonfatal heart attacks in people with . Chondroitin may work by inhibiting and by acting as an anticoagulant. The few doctors aware of these older studies sometimes recommend that people with a history of heart disease or who are at risk for heart attack take approximately 500 mg of chondroitin sulfate three times per day.
  • Pain Management

    Sprains and Strains

    Chondroitin sulfate may promote wound healing by providing the raw material needed by the body to manufacture molecules found in skin, tendons, ligaments, and joints.
    Sprains and Strains
    ×
     

    Glucosamine sulfate and chondroitin sulfate may both play a role in wound healing by providing the raw material needed by the body to manufacture molecules called glycosaminoglycans found in skin, tendons, ligaments, and joints.29 Test tube and animal studies have found that these substances, and others like them, can promote improved tissue healing.30,31,32,33 Injectable forms of chondroitin sulfate have been used in Europe for various types of sports-related injuries to tendons and joints,34,35,36,37 and one preliminary trial reported reduced pain and good healing in young athletes with chondromalacia patella (cartilage softening in the knee) who were given 750–1,500 mg per day of oral glucosamine sulfate.38 However, specific human trials of glucosamine and chondroitin sulfate for healing sprains and strains are lacking.

  • Kidney and Urinary Tract Health

    Kidney Stones

    Chondroitin sulfate may help reduce the risk of kidney stone formation. One trial found that glycosamionoglycans significantly lowered urinary oxalate levels, which reduces the risk of stone formation.
    Kidney Stones
    ×
     

    Chondroitin sulfate may play a role in reducing the risk of kidney stone formation. One trial found 60 mg per day of glycosamionoglycans significantly lowered urinary oxalate levels in stone formers.39 Chondroitin sulfate is a type of glycosaminoglycan. A decrease in urinary oxalate levels should reduce the risk of stone formation.

What Are Star Ratings?
×
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support.

Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.

For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.

Temp Title
×
Temp Text

References

1. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.

2. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75 [review].

3. Kerzberg EM, Roldan EJA, Castelli G, Huberman ED. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthritis. Scand J Rheum 1987;16:377.

4. Baici A, Hörler D, Moser B, et al. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992;12:81-8.

5. Rovetta G. Galactosaminoglycuronoglycan sulfate (Matrix) in therapy of tibiofibular osteoarhtirits of the knee. Drugs Exp Clin Res 1991;17:53-7.

6. Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995;45:918-25.

7. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998;6(Supplement A):14-21.

8. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39-46.

9. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 1998;6(Suppl A):37-8.

10. Bucsi L, PoĂłr G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):31-6.

11. Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3X400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6(Suppl A):25-30.

12. Pipitone V, Ambanelli U, Cervini C, et al. A multicenter, triple-blind study to evaluate galactosaminoglucuronoglycan sulfate versus placebo in patients with femorotibial gonarthritis. Curr Ther Res 1992;52:608-38.

13. Bazières B, Loyau G, Menkès CJ, et al. Le chondroïtine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Rev Rhum Mal Ostéoartic 1992;59:466-72 [in French].

14. Conrozier T, Vignon E. Die Wirkung von Chondroitinsulfat bei der Behandlung der HĂĽft Gelenksarthrose. Eine Doppelblindstudie gegen Placebo. Litera Rheumatologica 1992;14:69-75 [in German].

15. L'Hirondel JL. Klinische Doppelblind-Studie mit oral verabreichtem Chondroitinsulfat gegen Placebo bei der tibiofermoralen Gonarthrose (125 Patienten). Litera Rheumatologica 1992;14:77-82 [in German].

16. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91.

17. Leeb BF, Petera P, Neumann K. Results of a multicenter study of chondroitin sulfate (Condrosulf) use in arthroses of the finger, knee and hip joints. Wien Med Wochenschr 1996;146:609-14.

18. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011;70:982-9.

19. Hollmann J, Schmidt A, von Bassewitz DB, et al. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis 1989;9:154–8.

20. Izuka K, Murata K, Nakazawa K, et al. Effects of chondroitin sulfates on serum lipids and hexosamines in atherosclerotic patients: With special reference to thrombus formation time. Jpn Heart J 1968;9:453–60.

21. Nakazawa K, Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Z Alternsforsch 1979;34:153–9.

22. Morrison LM, Enrick NL. Coronary heart disease: reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–87.

23. Rondanelli M, Miraglia N, Putignano P, et al. Short- and Long-Term Effectiveness of Supplementation with Non-Animal Chondroitin Sulphate on Inflammation, Oxidative Stress and Functional Status in Obese Subjects with Moderate Knee Osteoarthritis before and after Physical Stress: A Randomized, Double-Blind, Placebo-Controlled Trial. Antioxidants (Basel) 2020;9:1241.

24. Radhakrishnamurthy B, Ruiz HA, Srinivasan SR, et al. Studies of glycosaminoglycan composition and biologic activity of Vessel, a hypolipidemic agent. Atherosclerosis 1978;31:217–29.

25. Wegrowski J, Robert AM, Moczar M. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem Pharmacol 1984;33:3491–7.

26. Arai H, Kashiwagi S, Nagasaka Y, et al. Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophys 1999;367:1–8.

27. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: Preliminary report. Exp Med Surg 1969;27:278-89.

28. Morrison LM, Enrick NL. Coronary heart disease: reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–87.

29. Morrison LM, Murata K. Absorption, distribution, metabolism and excretion of acid mucopolysaccharides administered to animals and patients. In: Morrison LM, Schjeide OA, Meyer K. Coronary heart disease and the mucopolysaccharides (glycosaminoglycans). Springfield: Charles C. Thomas, 1974, 109–27.

30. Denuziere A, Ferrier D, Damour O, et al. Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes: biological properties. Biomaterials 1998;19:1275-85.

31. McCarty MF. Glucosamine for wound healing. Med Hypotheses 1996;47:273-5 [review].

32. Glade MJ. Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycans by arthritic equine cartilage tissues and chondrocytes. Am J Vet Res 1990;51:779-85.

33. Prudden JF, Wolarsky ER, Balassa L. The acceleration of healing. Surg Gynecol Obstet 1969;128:1321-6 [review].

34. Bucci L. Nutrition applied to injury rehabilitation and sports medicine. Boca Raton, FL: CRC Press, 1995, 193.

35. Sprengel H, Franke J, Sprengel A. Personal experiences in the conservative therapy of patellar chondropathy. Beitr Orthop Traumatol 1990;37:259–66 [in German].

36. Lysholm J. The relation between pain and torque in an isokinetic strength test of knee extension. Arthroscopy 1987;3:182–4.

37. Ziegler R, Rau R. Conservative or operative treatment for chondropathia patellae? Beitr Orthop Traumatol 1980;27:201–11 [in German].

38. Böhmer D, Ambrus P, Szögy A, et al. Treatment of chondropathia patellae in young athletes with glucosamine sulfate. In: Bachl N, Prokop L, Suckert R, eds. Current topics in sports medicine. Vienna: Urban & Schwarzenberg, 1984, 799.

39. Baggio B, Gambaro G, Marchini F, et al. Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans. Lancet 1991;338:403-5.

40. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998;6(Supplement A):14-21.

41. De Klerk DP, Lee DV, Human HJ. Glycosaminoglycans of human prostatic cancer. J Urol 1984;131:1008-12.

42. Ricciardelli C, Quinn DI, Raymond WA, et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res 1999;59:2324-8.

Copyright © 2024 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2024.